Background {#Sec1}
==========

Obstruction in the outflow pathway of the aqueous humor due to structural changes in the trabecular meshwork (TM) and the resultant elevated intraocular pressure (IOP) are believed to be one of the major contributing factors leading to the damage of the optic nerve head (ONH), retinal ganglion cell (RGC) death and subsequent loss of vision in glaucoma \[[@CR1]\]. The precise molecular mechanisms or genetic factors responsible for TM alteration and outflow resistance leading to glaucomatous damage to the eye are still unclear. Recent studies suggest an essential role of growth factors in maintaining ocular homeostasis in tissues related to glaucoma, and alterations in growth factor or their receptors may induce structural or functional changes in the TM or ONH and thereby play an important role in the pathogenesis of glaucoma \[[@CR2], [@CR3]\].

Members of the transforming growth factor-β (TGF-β) superfamily of growth factors have been implicated in glaucoma pathogenesis \[[@CR4]--[@CR6]\]. Recent genome-wide association study (GWAS) reported three loci containing genes (*CDKN2B-AS1*, *TGFBR3-CDC7* and *FNDC3B*) linked to POAG which may contribute to the regulation of the TGF-β signaling \[[@CR7]\]. Besides TGF-β, the members of the TGF-β family also include bone morphogenetic proteins (BMPs), activins and other signaling molecules \[[@CR8]\].

BMPs are known to control a variety of biological functions in the cells \[[@CR9]\]. Like the TGF-β cytokines, BMPs induce signaling by binding to the cell surface BMP type I and type II serine/threonine kinase receptors. Following ligand binding, the type II BMP receptor phosphorylates the type I BMP receptor to initiate downstream BMP signaling via Smad or non-Smad pathway to regulate transcription of target genes \[[@CR9]\]. Activin A receptor type I (*ACVR1*) is a BMP type I receptor of the TGF-β receptor subfamily. Mutations in the *ACVR1* gene are known to cause fibrodysplasia ossificans progressiva (FOP), a genetic disease characterized by progressive heterotopic ossification \[[@CR10], [@CR11]\]. Besides, the inactivation or over-activation of these receptors due to genetic variations or altered (mis)expression are also reported to be involved in cardiovascular, reproductive system and cancer \[[@CR11]\]. *Acvr1* has also been reported to function as a tumor suppressor gene in the mouse lens \[[@CR12]\]. Bone morphogenetic protein 6 (BMP6) is an ACVR1 ligand related to the TGF-β superfamily. A reduction in the levels of BMP6 has been reported in neovascular and early age-related macular degeneration (AMD) \[[@CR13], [@CR14]\] In-vitro studies have shown that BMP6 may protect the retinal pigment epithelial (RPE) cells from oxidative stress and apoptosis \[[@CR14]\]. Besides, the expression of BMP6 (and activin A) has also been associated with conjunctival scarring \[[@CR15]\].

It can thus be speculated that members of the complex TGF-β/BMP signaling pathway may have a role in maintaining TM homeostasis as well as glaucoma pathogenesis \[[@CR16]\]. Likewise, any alterations in the expression of genes involved in BMP signaling as a result of genetic variants, may have functional consequences and influence the disease risk \[[@CR9]\]. Accordingly, we investigated genetic variations in members of the TGF-β/BMP signaling and their association with primary angle-closure glaucoma (PACG) and pseudoexfoliation glaucoma (PXG). The study focused on two variants in the 3′ untranslated region (UTR), rs12997 in *ACVR1*, and rs1043784 in *BMP6*. The variants rs12997 and rs1043784 located in the 3'UTR region of the *ACVR1* and *BMP6* genes, respectively, and may result in disruption of microRNA (miRNA)/mRNA binding \[[@CR17]\], thereby alter their expression and interfere in subsequent downstream processes and influence the disease risk.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

A retrospective case-control study was conducted. The study was approved by the Institutional Ethical Committee at College of Medicine (approval number \# 08--657) and conformed to the principles of the Declaration of Helsinki. All the participants provided a written informed consent. Patients of Saudi origin with clinical diagnosis of PACG, PXG and normal controls were enrolled at King Abdulaziz University Hospital, Riyadh, Saudi Arabia.

PACG patients (*n* = 101) were diagnosed based on clinical evidence of anatomically closed angle showing the occurrence of appositional or synnechial closure of the anterior chamber angle (at least 270^o^ of the angle is occluded); raised IOP (≥21 mmHg); presence of optic disk damage with cup/disc ratio of at least 0.7 (in at least one eye); and loss of peripheral or advanced visual field \[[@CR18]\]. PXG patients (*n* = 95) showed the presence of flaky exfoliation material along the pupil edges or anterior lens capsule, glaucomatous optic neuropathy and associated visual field loss, and high IOP in either or both the eyes as described previously \[[@CR19]\]. Patients harboring secondary forms of glaucoma, history of optic neuropathies or visual impairment unrelated to glaucoma, steroid usage, ocular trauma, absence of sufficient fundus visualization for disk assessment, or refusal to enroll were excluded. A group of healthy Saudi Arab subjects (*n* = 250) recruited from our ophthalmology screening clinics served as controls. The participants were: \> 40 years of age, with normal IOP, and free from any form of glaucoma on clinical examination. Subjects refusing to participate were excluded.

Genotyping of rs12997 and rs1043784 {#Sec4}
-----------------------------------

TaqMan® assays, C\_\_\_7545093_10 and C\_\_\_2064624_20 (Catalog number: 4351379; Applied Biosystems Inc., Foster City, CA, USA) were used to genotype rs12997 and rs1043784, respectively on ABI 7500 Real-Time PCR System (Applied Biosystems) under conditions recommended by the manufacturer \[[@CR18]\].

Statistical analysis {#Sec5}
--------------------

Hardy-Weinberg Equilibrium (HWE), allele, and genotype associations were tested using Chi-square analysis. Besides, Student's *t*-test (2-groups) and one-way ANOVA (3-groups) was used to compare continuous variables. Regression analysis was performed to test the effects of multiple factors such as age, sex, and genotypes on POAG. Statistical tests were performed using SPSS version 22 (IBM Inc., Chicago, Illinois, USA). Besides, SNPStats online software (<https://www.snpstats.net/start.htm>) was also utilized for testing genotype associations. A *p* \< 0.05 (2-tailed) was considered significant. Bonferroni's correction was used to adjust for multiple testing and corrected *p*-values *\<* 0.01 was considered where applicable.

Results {#Sec6}
=======

Demographic data distribution {#Sec7}
-----------------------------

The demographic data of subjects included in the study is shown in Fig. [1](#Fig1){ref-type="fig"}. The patient groups were found to be older than the control group. The age difference was non-significant in PACG (*p* = 0.319) but significantly older in the PXG (*p* \< 0.001) as compared to controls. Similarly, in terms of gender distribution, there was preponderance of men, except in the PACG group. However, the distribution was non-significant in both the PACG (*p* = 0.080) and PXG (*p* = 0.100) groups as compared to controls. Fig. 1Demographic data distribution of subjects included in this study

Allele frequency of rs12997 {#Sec8}
---------------------------

The distribution of allele frequency of rs12997 according to glaucoma type and gender in cases and controls is shown in Table [1](#Tab1){ref-type="table"}. The control group showed no significant deviation from HWE. As shown in Table [1](#Tab1){ref-type="table"}, the minor allele frequency of rs12997 \[G\] allele showed a significant trend in PACG (*p* = 0.050), wherein gender-stratification showed that women with G allele exhibited a significant \~ 2-fold increased risk of PACG (*p* = 0.005). Likewise, PXG group also exhibited a significant trend (*p* = 0.056) but did not show any significant gender distribution. Table 1Minor allele frequency of rs12997\[G\] polymorphism in cases and controlsType GroupCases MAFControls MAFOdds ratio (95% confidence interval)***p***PACG Total0.410.331.40 (0.99--1.96)**0.050** Men0.350.360.97 (0.58--1.61)0.920 Women0.460.301.93 (1.21--3.07)**0.005**PXG Total0.410.331.39 (0.99--1.97)**0.056** Men0.410.361.24 (0.89--1.93)0.329 Women0.410.301.61 (0.92--2.82)0.092*Abbreviation*: *PACG* primary angle-closure glaucoma, *PXG* pseudoexfoliation glaucoma, *MAF* minor allele frequencySignificant and trend *p*-value in bold

Allele frequency of rs1043784 {#Sec9}
-----------------------------

The allele frequency distribution of rs1043784 according to glaucoma type and gender in cases and controls is shown in Table [2](#Tab2){ref-type="table"}. In contrast to rs12997, the minor allele \[C\] of rs1043784 showed no significant distribution either in the PACG (*p* = 0.475) or PXG cases (*p* = 0.446) as compared to controls. Furthermore, gender-stratification also yielded no significant association. Also, there was no significant deviation from HWE. Table 2Minor allele frequency of rs1043784\[C\] polymorphisms in cases and controlsType GroupCases MAFControls MAFOdds ratio (95% confidence interval)***p***PACG Total0.170.151.17 (0.75--1.82)0.475 Men0.190.151.27 (0.68--2.37)0.442 Women0.160.141.10 (0.59--2.06)0.751PXG Total0.170.151.19 (0.76--1.86)0.446 Men0.180.151.20 (0.68--2.12)0.360 Women0.160.141.14 (0.54--2.39)0.729*Abbreviation*: *PACG* primary angle-closure glaucoma, *PXG* pseudoexfoliation glaucoma, *MAF* minor allele frequency

Genotype analyses of rs12997 {#Sec10}
----------------------------

The genotype analyses of rs12997 according to glaucoma type and gender-stratification are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Association analysis was performed in co-dominant, dominant, recessive, over-dominant, and log-additive genetic models using SNPStats software. Table 3Association analysis of rs12997 variant in *ACVR1* with primary angle-closure glaucomaGroupGenetic ModelGenotypeControl\
n (%)PACG\
n (%)OR (95% CI)***p***AICBIC***p***^**§**^OverallCo-dominantA/A110 (44.4)42 (41.6)1.00**0.009**416.5428.1**0.02**A/G111 (44.8)35 (34.6)0.83 (0.49--1.39)G/G27 (10.9)24 (23.8)**2.33 (1.21--4.48)**DominantA/A110 (44.4)42 (41.6)1.000.64423.7431.40.900A/G-G/G138 (55.6)59 (58.4)1.12 (0.70--1.79)RecessiveA/A-A/G221 (89.1)77 (76.2)1.00**0.003**\*415.1422.8**0.009**G/G27 (10.9)24 (23.8)**2.55 (1.39--4.69)**Over-dominantA/A-G/G137 (55.2)66 (65.3)1.000.081420.9428.60.062A/G111 (44.8)35 (34.6)0.65 (0.40--1.06)Log-additive------1.36 (0.99--1.89)0.062420.4428.10.150MenCo-dominantA/A55 (41.0)22 (50.0)1.000.120200.8210.40.170A/G62 (46.3)13 (29.6)0.52 (0.24--1.14)G/G17 (12.7)9 (20.4)1.32 (0.51--3.41)DominantA/A55 (41.0)22 (50.0)1.000.300202.0208.40.170A/G-G/G79 (59.0)22 (50.0)0.70 (0.35--1.38)RecessiveA/A-A/G117 (87.3)35 (79.5)1.000.220201.6207.90.540G/G17 (12.7)9 (20.4)1.77 (0.73--4.32)Over-dominantA/A-G/G72 (53.7)31 (70.5)1.000.048199.2205.50.060A/G62 (46.3)13 (29.6)0.49 (0.23--1.01)Log-additive------0.98 (0.60--1.58)0.920203.1209.40.530WomenCo-dominantA/A55 (48.2)20 (35.1)1.00**0.010**214.5224**0.006**A/G49 (43.0)22 (38.6)1.23 (0.60--2.53)G/G10 (8.8)15 (26.3)**4.12 (1.60--10.66)**DominantA/A55 (48.2)20 (35.1)1.000.100219225.30.140A/G-G/G59 (51.8)37 (64.9)1.72 (0.89--3.32)RecessiveA/A-A/G104 (91.2)42 (73.7)1.00**0.003\***212.9219.1**0.002**G/G10 (8.8)15 (26.3)**3.71 (1.55--8.93)**Over-dominantA/A-G/G65 (57.0)35 (61.4)1.000.58221.4227.70.420A/G49 (43.0)22 (38.6)0.83 (0.44--1.60)Log-additive------**1.85 (1.17--2.92)0.0076**214.6220.8**0.008**^§^*p*-value adjusted for age and sex in overall group and by age in men and women groups; \*Best-fit model *p*-value. *Abbreviations*: *AIC* Akaike's information criterion, *BIC* Bayesian information criterion, *OR (95% CI)* Odds ratio (95% confidence interval), *PACG* primary angle-closure glaucoma. Note: Significant odds ratio and *p*-value in bold. Bonferroni corrected *p*-value is 0.01Table 4Association analysis of rs12997 variant in *ACVR1* with primary pseudoexfoliation glaucomaGroupGenetic ModelGenotypeControl\
n (%)PXG\
n (%)OR (95% CI)***p***AICBIC***p***^**§**^OverallCo-dominantA/A110 (44.4)34 (35.8)1.000.150407.0418.60.52A/G111 (44.8)44 (46.3)1.28 (0.76--2.16)G/G27 (10.9)17 (17.9)**2.04 (0.99--4.18)**^†^DominantA/A110 (44.4)34 (35.8)1.000.150406.7414.40.34A/G-G/G138 (55.6)61 (64.2)1.43 (0.88--2.33)RecessiveA/A-A/G221 (89.1)78 (82.1)1.000.091405.9413.60.37G/G27 (10.9)17 (17.9)1.78 (0.92--3.45)Over-dominantA/A-G/G137 (55.2)51 (53.7)1.000.800408.7416.40.7A/G111 (44.8)44 (46.3)1.06 (0.66--1.71)Log-additive------1.39 (0.99--1.97)**0.059\***405.2412.90.25MenCo-dominantA/A55 (41.0)23 (37.7)1.000.460246.8256.60.82A/G62 (46.3)26 (42.6)1.00 (0.51--1.96)G/G17 (12.7)12 (19.7)1.69 (0.70--4.09)DominantA/A55 (41.0)23 (37.7)1.000.660246.1252.70.83A/G-G/G79 (59.0)38 (62.3)1.15 (0.62--2.14)RecessiveA/A-A/G117 (87.3)49 (80.3)1.000.210244.8251.30.53G/G17 (12.7)12 (19.7)1.69 (0.75--3.79)Over-dominantA/A-G/G72 (53.7)35 (57.4)1.000.630246.1252.60.85A/G62 (46.3)26 (42.6)0.86 (0.47--1.59)Log-additive------1.24 (0.80--1.90)0.340245.42520.64WomenCo-dominantA/A55 (48.2)11 (32.4)1.000.230162.5171.50.45A/G49 (43.0)18 (52.9)1.84 (0.79--4.27)G/G10 (8.8)5 (14.7)2.50 (0.71--8.76)DominantA/A55 (48.2)11 (32.4)1.000.098160.8166.80.22A/G-G/G59 (51.8)23 (67.7)1.95 (0.87--4.37)RecessiveA/A-A/G104 (91.2)29 (85.3)1.000.330162.6168.60.54G/G10 (8.8)5 (14.7)1.79 (0.57--5.66)Over-dominantA/A-G/G65 (57.0)16 (47.1)1.000.310162.5168.50.38A/G49 (43.0)18 (52.9)1.49 (0.69--3.22)Log-additive------1.64 (0.92--2.93)0.091160.7166.70.22*Abbreviations*: *AIC* Akaike's information criterion, *BIC* Bayesian information criterion, *OR (95% CI)* Odds ratio (95% confidence interval), *PXG* pseudoexfoliation glaucoma. Note: Significant odds ratio and *p*-value (trend) in bold. Bonferroni corrected *p*-value is 0.01^§^*p*-value adjusted for age and sex in overall group and by age in men and women groups; ^†^A/A vs G/G *p*-value = **0.049**; \*Best-fit model *p*-value

As shown in Table [3](#Tab3){ref-type="table"}, rs12997 polymorphism showed a significant association with PACG in co-dominant and recessive models. The recessive model was observed to be the best-fit as indicated by the Akaike's information criterion and Bayesian information criterion values. Subjects carrying G/G genotype were at significantly increased (\> 2-fold) risk of glaucoma. The effect remained significant after adjustment for age, sex, and Bonferroni correction (p~correction~ = 0.05/5 = 0.01) in the recessive model. However, the significance was lost after Bonferroni correction in the co-dominant model. Furthermore, the association was significant in women but not in men, and the p-value showed significant association even after adjustment for age and multiple testing (Table [3](#Tab3){ref-type="table"}).

Analysis of rs12997 in PXG patients showed a trend towards association as compared to controls (Table [4](#Tab4){ref-type="table"}) with G/G genotype resulting in a 2-fold increased of disease (*p* = 0.049) in co-dominant model. No gender-specific association was observed with PXG (Table [4](#Tab4){ref-type="table"}). However, the trend did not survive the Bonferroni correction.

Genotype analyses of rs1043784 {#Sec11}
------------------------------

Rs1043784 variant did not show any significant association with PACG and PXG (Table [5](#Tab5){ref-type="table"}). Besides, a genotype analysis of rs1043784 in PACG and PXG cases in comparison to controls according to gender also did not reveal any gender-specific association in any of the tested genetic models (*data not shown*). Table 5Association analysis of rs1043784 variant in *BMP6* in cases and controls according to glaucoma typesGroupGenetic ModelGenotypeControl\
n (%)Cases\
n (%)OR (95% CI)***p***AICBIC***p***^**§**^PACGCo-dominantT/T184 (73.6)71 (69.6)1.000.75429.2440.80.73C/T57 (22.8)27 (26.5)1.23 (0.72--2.09)C/C9 (3.6)4 (3.9)1.15 (0.34--3.86)DominantT/T184 (73.6)71 (69.6)1.000.45427.2434.90.66C/T-C/C66 (26.4)31 (30.4)1.22 (0.73--2.02)RecessiveT/T-C/T241 (96.4)98 (96.1)1.000.89427.8435.50.63C/C9 (3.6)4 (3.9)1.09 (0.33--3.63)Over-dominantT/T-C/C193 (77.2)75 (73.5)1.000.47427.24350.5C/T57 (22.8)27 (26.5)1.22 (0.72--2.07)Log-additive------1.16 (0.76--1.76)0.5427.34350.85PXGCo-dominantT/T184 (73.6)64 (67.4)1.000.29409.6421.10.24C/T57 (22.8)29 (30.5)1.46 (0.86--2.48)C/C9 (3.6)2 (2.1)0.64 (0.13--3.04)DominantT/T184 (73.6)64 (67.4)1.000.25408.8416.50.24C/T-C/C66 (26.4)31 (32.6)1.35 (0.81--2.26)RecessiveT/T-C/T241 (96.4)93 (97.9)1.000.46409.5417.20.38C/C9 (3.6)2 (2.1)0.58 (0.12--2.72)Over-dominantT/T-C/C193 (77.2)66 (69.5)1.000.14407.9415.60.13C/T57 (22.8)29 (30.5)1.49 (0.88--2.52)Log-additive------1.18 (0.76--1.83)0.46409.5417.20.45*Abbreviations*: *OR (95% CI)* Odds ratio (95% confidence interval), *AIC* Akaike's information criterion, *BIC* Bayesian information criterion, *PACG* primary angle-closure glaucoma, *PXG* pseudoexfoliation glaucoma^§^*p*-value adjusted for age and sex in overall group and by age in men and women groups

Effect of age, sex, and genotypes on disease outcome {#Sec12}
----------------------------------------------------

Table [6](#Tab6){ref-type="table"} shows the results of regression analysis of age, sex, rs12997, and rs1043784 variants on glaucoma outcomes. The regression analysis revealed that rs12997 and G/G genotype was a significant predictor of PACG independent of age, sex, and rs1043784 genotypes. Likewise, age, rs12997 and G/G genotype showed significant effect on PXG outcome. Table 6Regression analysis to determine the effect age, sex and polymorphisms on glaucoma riskGroup\
VariablesBSEWaldOdds ratio (95% confidence interval)***p*PACG** Age0.0160.0160.9951.02 (0.98--1.04)0.319 Sex−0. 4670.2553.3710. 62 (0.38--1.03)0. 066 Rs129977.904**0.019** A/G−0. 2620. 2810. 8700.77 (0.44--1.33)0.351 G/G0.7480.3544.4572.11 (1.05--4.23)**0.035** Rs10437840.6750.714 T/C0.1850.2970.3891.20 (0.67--2.15)0.533 C/C−0.3290.7090.2160.72 (0.18--2.88)0.642 Constant−1.4980.9612.430.2230.119**PXG** Age0.0750.01720.4881.08 (1.04--1.11)**0.000** Sex−0.2990.2781.1591.34 (0.78--2.32)0.282 Rs129976.227**0.044** A/G0.1880.2950.4041.20 (0.67--2.15)0.525 G/G1.0330.4186.1072.81 (1.23--6.37)**0.013** Rs10437842.9320.231 T/C0.4550.3032.261.57 (0.87--2.85)0.133 C/C−0.5590.8540.4270.57 (0.10--3.05)0.513 Constant−6.0281.09530.3180.0020.000*Abbreviations*: *PACG* primary angle-closure glaucoma, *PXG* pseudoexfoliation glaucomaSignificant *p*-value in bold

Effect on genotypes on clinical indices of glaucoma {#Sec13}
---------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} shows the genotype effect of rs12997 on IOP, cup/disc ratio and number of antiglaucoma medications in the PACG and PXG groups. These are clinical indicators related to the severity of the disease. The distribution showed no significant effect on any of these phenotypes, except for cup/disc ratio in PXG cases (*p* = 0.004). Post-hoc analysis showed that A/G genotype exhibited increased cup/disc ratio as compared to A/A (wild-type) genotype (*p* = 0.005). Figure [3](#Fig3){ref-type="fig"} shows the genotype effect of rs1043784 on IOP, cup/disc ratio and number of antiglaucoma medications in the PACG and PXG groups. The genotype distribution showed no significant effect on any of these phenotypes in both the PACG and PXG patient groups. Fig. 2Genotype effects of rs12997 variant on intraocular pressure (IOP), cup/disc ratio and number of antiglaucoma medication in (**a**) PACG and (**b**) PXG patient groupsFig. 3Genotype effects of rs1043784 variant on intraocular pressure (IOP), cup/disc ratio and number of antiglaucoma medication in (**a**) PACG and (**b**) PXG patient groups

Discussion {#Sec14}
==========

In the present study, we report a previously unreported association between variant rs12997 in the *ACVR1* gene involved in BMP signaling and patients with PACG and PXG in a Saudi cohort.

The regulation of *ACVR1* (also known as *ALK2*) gene expression is still not completely understood. ACVR1 can function via the TGF-β/BMP signaling through a variety of different mechanisms. Mutations in *ACVR1* have been reported to show increased responsiveness to certain BMP ligand activation in a variety of cell types, leading to over-activation of *ACVR1* and dysregulated BMP signaling \[[@CR20]--[@CR22]\]. Activins can also interact with ACVR1, and compete with BMP ligands \[[@CR23]\]. The competition for ligand may cause dysregulated signaling outcomes due to any imbalance in the levels of epxression between type I and type II BMP receptors \[[@CR24]\]. Besides, abnormal ACVR1 activity is also reported to be proinflammatory, causing altered immune function via NF-κB and p38MAPK activity signaling leading to pathological outcomes \[[@CR25]\]. Besides, association of genetic variants in *ACVR1* has been reported in breast cancer \[[@CR26]\], and with anti-Mullerian hormone level in women having polycystic ovary syndrome \[[@CR27]\].

Interestingly, ACVR1 has been reported to function as a critical regulator of the BMP/Wnt signaling pathway to promote proliferation and metastasis \[[@CR26], [@CR28]\]. Genes involved in canonical and non-canonical Wnt signaling pathways have been reported to be expressed in the human TM and the role of the Wnt signaling pathway in the regulation of TM homeostasis and IOP is well documented \[[@CR29], [@CR30]\]. Also, over-expression of secreted frizzled-related protein-1 (sFRP-1), a Wnt signaling antagonist, in glaucomatous TM cells has been demonstrated to be responsible for elevated IOP in glaucoma \[[@CR31]\]. Similarly, ACVR1 has been shown to inhibit Wnt signaling in osteoblasts by suppressing Wnt inhibitors SOST and DKK1 \[[@CR32]\]. Likewise, *Acvr1*-deficiency (loss-of-function) was found to increase osteogenesis by activating Wnt signaling and decreasing the expression levels of these Wnt inhibitors \[[@CR32]\]. Based on these studies, it can be speculated there is a plausible role for ACVR1 in TM modulation and IOP regulation via Wnt signaling regulation.

PACG is a more common form of glaucoma in Asia \[[@CR33], [@CR34]\], involving anatomical obstruction of the outflow pathway \[[@CR1]\]. Likewise, PXG is a severe form of open-angle glaucoma associated with worse prognosis. PXG is characterized by the abnormal deposition of pseudoexfoliative material (fibrillar extracellular matrix (ECM)) in the anterior segment of the eye causing the obstruction \[[@CR35]\]. It is difficult to elucidate the precise mechanism(s) by which the variant rs12997 in *ACVR1* may influence the risk of these glaucoma types. Nevertheless, rs12997 is located in the 3'UTR region of the gene, which are known to regulate mRNA stability. The functional analysis of the 3'UTR region of *ACVR1* has reported the involvement of specific miRNAs in regulating its gene expression \[[@CR36]\]. It has been observed that rs12997 variation in *ACVR1* may affect the binding of miR-330-3p and result in loss of *ACVR1* regulation \[[@CR17]\]. Hence, *ACVR1* with G allele may result in its over-expression as compared to the wild-type allele, thereby showing an association with PACG and PXG by mechanism(s) regulating the ACVR1/BMP/Wnt signaling pathway as described above. Besides, Wnt signaling pathway play a key role in ECM cell behaviour and elasticity \[[@CR37]\], and studies have demonstrated a link between Wnt antagonism and increased TM stiffness that may contribute to glaucoma progression \[[@CR38]\]. It is thus possible that over-expression of *ACVR1* may result in dysregulated Wnt signaling causing ECM abnormalities in the TM and elevated IOP. Further in-vitro and molecular studies are needed to support this hypothesis.

Our study showed no association between variant rs1047384 in *BMP6* and PACG and PXG, indicating BMP6 may not have a major role in glaucoma pathogenesis. However, *BMP6* locus has been associated with lung function in a GWAS \[[@CR39]\]. Likewise, animal studies have provided evidence for a developmental role of BMP4 and/or TGF-β2 in mesenchyme morphogenesis in the anterior eye \[[@CR40]\]. Thus the role of other variants in *BMP6* or other BMPs in glaucoma cannot be ruled out and needs further investigations \[[@CR41]\].

The results of this study need cautious interpretation due to its certain limitations. The study examined a relatively small sample size. On the basis of MAF observed in our study population and assuming an OR of 2.0 (α = 0.05), the study exhibited a power of 0.82 and 0.80 for rs12997 association in PACG and PXG, respectively. Likewise, variant rs1043784 demonstrated powers of 0.70 and 0.68 to detect association with PACG and PXG, respectively. However, to detect an effect of 1.5 or less, as is most commonly seen in genetic association investigations, a multicenter study with larger sample-size needs to be performed to confirm these results. Besides, our results do not provide any functional/mechanistic evidence for the role of rs12997 in *ACVR1* in PACG and PXG. Furthermore, linkage with other causal variant(s), gene-gene or gene-environment cannot be ruled out.

Conclusions {#Sec15}
===========

In conclusion, our study reports for the first time that genetic variant rs12997 in the *ACVR1* gene is associated with PACG and PXG, and suggests that *ACVR1*, a member of the BMP signaling pathway may play an important role in the complex pathogenesis of these diseases. However, as pointed out earlier, our results need to be replicated in other cohorts of different ethnicity and in a large population-based sample size to draw definite conclusions and evaluate the utility of this variant/gene as a potential genetic biomarker in glaucoma. Besides, based on the reports of miRNA-based regulation of *ACVR1* \[[@CR26], [@CR36]\], understanding the underlying mechanisms of the *ACVR1* gene biology may offer potential therapeutic drug target in glaucoma.

ACVR1

:   Activin A receptor type I

AMD

:   Age-related macular degeneration

BMP

:   Bone morphogenic proteins

BMP6

:   Bone morphogenetic protein 6

CI

:   Confidence interval

ECM

:   Extracellular matrix

FOP

:   Fibrodysplasia ossificans progressive

HWE

:   Hardy-Weinberg equilibrium

IOP

:   Intraocular pressure

miRNA

:   MicroRNA

OR

:   Odds ratio

ONH

:   Optic nerve head

PACG

:   Primary angle-closure glaucoma

PXG

:   Pseudoexfoliation glaucoma

RGC

:   Retinal ganglion cell

RPE

:   Retinal pigment epithelia

TM

:   Trabecular meshwork

TGF-β

:   Transforming growth factor-β

UTR

:   Untranslated region

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors would like to thank the Vice Deanship of Scientific Research Chair, Glaucoma Research Chair in Ophthalmology, King Saud University. We also thank our clinical coordinator Mr. Abdulrahman Al-Mosa for his assistance in the work.

AAK: Conceptualization, experimental design, analysis, data interpretations, wrote and edited the manuscript; TS, TAA: sample preparation, genotyping and data acquisition, manuscript editing and revision; EAO, FAA: conceptualization, subject recruitment, clinical diagnosis, data interpretation, manuscript editing and revision. SAA: conceptualization, experimental design, recruitment, clinical diagnosis, data interpretation, manuscript editing and revision. All authors read and approved the final manuscript.

This work was supported by King Saud University through Vice Deanship of Scientific Research Chair and Glaucoma Research Chair in Ophthalmology, but had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

The study adhered to the tenets of the Declaration of Helsinki and had received approval from the Institutional Review Board and Research Ethics Committee of College of Medicine, King Saud University, Riyadh, Saudi Arabia (approval number \#08--657). Written, informed consent was obtained from all participants before their inclusion in this study.

Not applicable.

The authors declare that they have no competing interests. .
